BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Cheng M, Yang Q, Liu Y, Zhao M, Du X, Sun J, Shu W, Huang Z, Bi J, Xu X, Du H. SETD3 Methyltransferase Regulates PLK1 Expression to Promote In Situ Hepatic Carcinogenesis. Front Oncol 2022;12:882202. [DOI: 10.3389/fonc.2022.882202] [Reference Citation Analysis]
2 Heidari Z, Asemi-Rad A, Moudi B, Mahmoudzadeh-Sagheb H. mRNA expression and epigenetic-based role of chromodomain helicase DNA-binding 5 in hepatocellular carcinoma. J Int Med Res 2022;50:3000605221105344. [PMID: 35808817 DOI: 10.1177/03000605221105344] [Reference Citation Analysis]
3 Xing M, Li J. Diagnostic and prognostic values of pyroptosis-related genes for the hepatocellular carcinoma. BMC Bioinformatics 2022;23:177. [PMID: 35562678 DOI: 10.1186/s12859-022-04726-7] [Reference Citation Analysis]
4 Bekric D, Ocker M, Mayr C, Stintzing S, Ritter M, Kiesslich T, Neureiter D. Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers (Basel) 2022;14:1826. [PMID: 35406596 DOI: 10.3390/cancers14071826] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jiang Y, Lin L, Lv H, Zhang H, Jiang L, Ma F, Wang Q, Ma X, Yu S. . MBE 2022;19:7178-200. [DOI: 10.3934/mbe.2022339] [Reference Citation Analysis]
6 Moldogazieva NT, Zavadskiy SP, Sologova SS, Mokhosoev IM, Terentiev AA. Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Rev Mol Diagn 2021;:1-18. [PMID: 34582293 DOI: 10.1080/14737159.2021.1987217] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Sosnowska M, Kutwin M, Strojny B, Wierzbicki M, Cysewski D, Szczepaniak J, Ficek M, Koczoń P, Jaworski S, Chwalibog A, Sawosz E. Diamond Nanofilm Normalizes Proliferation and Metabolism in Liver Cancer Cells. Nanotechnol Sci Appl 2021;14:115-37. [PMID: 34511890 DOI: 10.2147/NSA.S322766] [Reference Citation Analysis]
8 Yu C, Rao D, Zhu H, Liu Q, Huang W, Zhang L, Liang H, Song J, Ding Z. TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27. Biomed Res Int 2021;2021:4708439. [PMID: 34423034 DOI: 10.1155/2021/4708439] [Reference Citation Analysis]
9 Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang Y, Wei H, Fan L, Fang M, He X, Lu B, Pang Z. CLEC4s as Potential Therapeutic Targets in Hepatocellular Carcinoma Microenvironment. Front Cell Dev Biol 2021;9:681372. [PMID: 34409028 DOI: 10.3389/fcell.2021.681372] [Reference Citation Analysis]
11 Blidisel A, Marcovici I, Coricovac D, Hut F, Dehelean CA, Cretu OM. Experimental Models of Hepatocellular Carcinoma-A Preclinical Perspective. Cancers (Basel) 2021;13:3651. [PMID: 34359553 DOI: 10.3390/cancers13153651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
12 Lv C, Li XJ, Hao LX, Zhang S, Song Z, Ji XD, Gong B. Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinoma. Clin Transl Oncol 2021. [PMID: 34282556 DOI: 10.1007/s12094-021-02673-y] [Reference Citation Analysis]
13 Singh P, Kairuz D, Arbuthnot P, Bloom K. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World J Gastroenterol 2021; 27(23): 3182-3207 [PMID: 34163105 DOI: 10.3748/wjg.v27.i23.3182] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ho YJ, Chang J, Yeh KT, Gong Z, Lin YM, Lu JW. Prognostic and Clinical Implications of WNK Lysine Deficient Protein Kinase 1 Expression in Patients With Hepatocellular Carcinoma. In Vivo 2020;34:2631-40. [PMID: 32871793 DOI: 10.21873/invivo.12081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Moldogazieva NT, Zavadskiy SP, Terentiev AA. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine. Cancer Genomics Proteomics 2021;18:369-83. [PMID: 33994362 DOI: 10.21873/cgp.20266] [Reference Citation Analysis]
16 Sartorius K, An P, Winkler C, Chuturgoon A, Li X, Makarova J, Kramvis A. The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA Dysregulation. Front Immunol 2021;12:661204. [PMID: 33995383 DOI: 10.3389/fimmu.2021.661204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kabel AM, Arab HH, Abd Elmaaboud MA. Attenuation of diethyl nitrosamine-induced hepatocellular carcinoma by taxifolin and/or alogliptin: The interplay between toll-like receptor 4, transforming growth factor beta-1, and apoptosis. Hum Exp Toxicol 2021;40:1710-20. [PMID: 33840231 DOI: 10.1177/09603271211008496] [Reference Citation Analysis]
18 Ocker M, Mayr C, Kiesslich T, Stintzing S, Neureiter D. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers (Basel) 2021;13:1558. [PMID: 33805268 DOI: 10.3390/cancers13071558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Afaloniati H, Poutahidis T, Giakoustidis A, Gargavanis A, Giakoustidis D, Angelopoulou K. Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components. Mol Biol Rep 2021;48:551-62. [PMID: 33393006 DOI: 10.1007/s11033-020-06089-9] [Reference Citation Analysis]
20 Woeste MR, Geller AE, Martin RCG 2nd, Polk HC Jr. Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. Ann Surg Oncol 2021;28:1499-510. [PMID: 33393028 DOI: 10.1245/s10434-020-09414-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhang B, Zhou Q, Xie Q, Lin X, Miao W, Wei Z, Zheng T, Pang Z, Liu H, Chen X. SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma. Aging (Albany NY) 2020;13:2803-21. [PMID: 33408271 DOI: 10.18632/aging.202329] [Reference Citation Analysis]
22 Vanderborght B, De Muynck K, Lefere S, Geerts A, Degroote H, Verhelst X, Van Vlierberghe H, Devisscher L. Effect of isoform-specific HIF-1α and HIF-2α antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model. Oncotarget 2020;11:4504-20. [PMID: 33400730 DOI: 10.18632/oncotarget.27830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Fu H, Zhang Y, Chen Y, Chen J, Chen P. CSN1 facilitates proliferation and migration of hepatocellular carcinoma cells by upregulating cyclin A2 expression. Mol Med Rep 2021;23:46. [PMID: 33200803 DOI: 10.3892/mmr.2020.11684] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Vanderborght B, Lefere S, Vlierberghe HV, Devisscher L. The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells 2020;9:E2382. [PMID: 33143149 DOI: 10.3390/cells9112382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Nagaraja SS, Subramanian U, Nagarajan D. Radiation-induced H3K9 methylation on E-cadherin promoter mediated by ROS/Snail axis : Role of G9a signaling during lung epithelial-mesenchymal transition. Toxicol In Vitro 2021;70:105037. [PMID: 33148527 DOI: 10.1016/j.tiv.2020.105037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
26 Ocker M, Neureiter D. Predicting the outcome of patients with hepatocellular carcinoma: new approaches beyond established clinical scoring systems. Expert Rev Gastroenterol Hepatol 2021;15:111-3. [PMID: 32985933 DOI: 10.1080/17474124.2021.1829472] [Reference Citation Analysis]
27 Deepak P, Siddalingam R, Kumar P, Anand S, Thakur S, Jagdish B, Jaiswal S. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. Journal of Drug Delivery Science and Technology 2020;59:101837. [DOI: 10.1016/j.jddst.2020.101837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Wang A, Meng J, Liu H, Li C, Zhou Z. Long non-coding RNA BCAR4 promotes liver cancer progression by regulating proliferation, migration and invasion. Oncol Lett 2020;20:2779-87. [PMID: 32782595 DOI: 10.3892/ol.2020.11826] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Ocker M. Dissecting the immune cell landscape in hepatocellular carcinoma-are we understanding complexity? Ann Transl Med 2020;8:666. [PMID: 32617286 DOI: 10.21037/atm.2020.03.170] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Afaloniati H, Angelopoulou K, Giakoustidis A, Hardas A, Pseftogas A, Makedou K, Gargavanis A, Goulopoulos T, Iliadis S, Papadopoulos V, Papalois A, Mosialos G, Poutahidis T, Giakoustidis D. HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice. Onco Targets Ther 2020;13:5575-88. [PMID: 32606772 DOI: 10.2147/OTT.S250233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Ma A, Zhang R. Diosmetin Inhibits Cell Proliferation, Induces Cell Apoptosis and Cell Cycle Arrest in Liver Cancer. Cancer Manag Res 2020;12:3537-46. [PMID: 32547191 DOI: 10.2147/CMAR.S240064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
32 Al Mamun A, Wu Y, Jia C, Munir F, Sathy KJ, Sarker T, Monalisa I, Zhou K, Xiao J. Role of pyroptosis in liver diseases. Int Immunopharmacol 2020;84:106489. [PMID: 32304992 DOI: 10.1016/j.intimp.2020.106489] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
33 Dai X, Huang R, Hu S, Zhou Y, Sun X, Gui P, Yu Z, Zhou P. A novel miR-0308-3p revealed by miRNA-seq of HBV-positive hepatocellular carcinoma suppresses cell proliferation and promotes G1/S arrest by targeting double CDK6/Cyclin D1 genes. Cell Biosci 2020;10:24. [PMID: 32128112 DOI: 10.1186/s13578-020-00382-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Roderburg C, Wree A, Demir M, Schmelzle M, Tacke F. The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepat Oncol 2020;7:HEP17. [PMID: 32273975 DOI: 10.2217/hep-2019-0007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
35 Tang T, Tao X, Bao X, Chen J, Dai J, Ye J, Yan Y. Mitofusin-2 (Mfn-2) Might Have Anti-Cancer Effect through Interaction with Transcriptional Factor SP1 and Consequent Regulation on Phosphatidylinositol Transfer Protein 3 (PITPNM3) Expression. Med Sci Monit 2020;26:e918599. [PMID: 31955176 DOI: 10.12659/MSM.918599] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhao H, Wang Y, Liu Y, Hao X, Wei H, Xie W. The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular Mechanism. Anal Cell Pathol (Amst) 2019;2019:5901083. [PMID: 31915594 DOI: 10.1155/2019/5901083] [Reference Citation Analysis]
37 Iuamoto LR, Meyer A. Commentary on "The risk factors for long-term survival outcome in solitary hepatocellular carcinoma up to 2 cm: Propensity score matching analysis in a population cohort with a high rate of HBV infection". Int J Surg 2019;72:144-5. [PMID: 31707012 DOI: 10.1016/j.ijsu.2019.10.045] [Reference Citation Analysis]
38 Klieser E, Mayr C, Kiesslich T, Wissniowski T, Fazio PD, Neureiter D, Ocker M. The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications. Int J Mol Sci 2019;20:E5266. [PMID: 31652839 DOI: 10.3390/ijms20215266] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]